Capsida Biotherapeutics

Capsida Biotherapeutics

  • Founded: 2020
  • Location: Thousand Oaks, CA
  • Employee range: 50 - 200
  • Clinical stage: RD
  • Therapy area: CNS disorders
  • Drug types: RAR, NEU, PED, OPH
  • Lead product: Undisclosed
  • Product link:
  • Funding: $140M Apr 2021
  • Investors: Versant Ventures, Westlake Village BioPartners

job board

Short description:

AAV Gene Therapy

Drug notes:

Undisclosed RD eye diseases

Long description:

Capsida Biotherapeutics is developing tissue-targeted, non-invasive gene therapies for rare and common diseases. Capsida’s approach is to use an intravenous delivery of a single, engineered capsid that can target individual or multiple organs simultaneously while limiting exposure to non-targeted organs. These capsids can deliver therapies that achieve gene replacement and gene editing and can therefore treat both monogenic and polygenic diseases. Capsida optimizes their capsids by using their automated, high-throughput biological screening method and is initially focused on targeting disorders of the central nervous system which have significant prevalence and unmet need.


Capsida Biotherapeutics
Sr. Scientist, In Vivo Pharmacology
Thousand Oaks, California, Stati Uniti d'America|12 days ago

© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy